JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating for Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $22.
September 27, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Enanta Pharma, maintaining a $22 price target. This suggests confidence in the company's potential for growth.
The reiteration of a Market Outperform rating and maintenance of a $22 price target by JMP Securities indicates a positive outlook on Enanta Pharma's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100